Monte Rosa Therapeutics Files 8-K on Security Holder Vote Matters

TL;DR

Monte Rosa (MRSA) is holding a shareholder vote, details to come.

AI Summary

On June 12, 2024, Monte Rosa Therapeutics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Delaware with its principal executive offices in Boston, MA, is involved in the biological products sector.

Why It Matters

This filing signals that Monte Rosa Therapeutics is engaging its security holders in a formal voting process, which could pertain to significant corporate decisions or governance changes.

Risk Assessment

Risk Level: low — The filing is a routine procedural update regarding a vote of security holders and does not disclose new financial or operational risks.

Key Numbers

• 001-40522 — SEC File Number (Identifies the company's filing history with the SEC.)
• 84-3766197 — I.R.S. Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Monte Rosa Therapeutics, Inc. (company) — Registrant
• June 12, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Boston, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq

Filing Documents

• glue-20240612.htm (8-K) — 57KB
• 0000950170-24-072407.txt ( ) — 178KB
• glue-20240612.xsd (EX-101.SCH) — 30KB
• glue-20240612_htm.xml (XML) — 5KB

07 Submission of Matters to Vote of Security Holders

Item 5.07 Submission of Matters to Vote of Security Holders On June 12, 2024, Monte Rosa Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 17, 2024, the record date for the Annual Meeting, there were 50,325,324 outstanding shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The Company's stockholders voted on the following matters, which are described in detail in the Company's definitive proxy statement on Schedule 14A (the "Proxy Statement"): (i) to elect two directors, Markus Warmuth, M.D. and Ali Behbahani, M.D., as Class III directors of the Company, each to serve for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Proposal 1 - Election of Class III Director Nominees The stockholders of the Company elected Markus Warmuth, M.D. and Ali Behbahani, M.D. as Class III directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2027 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class III directors were as follows: Votes For Votes Withheld Broker Non-Votes Markus Warmuth, M.D. 39,473,886 84,415 910,598 Ali Behbahani, M.D. 23,794,947 15,763,354 910,598 Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Th

View Full Filing

View this 8-K filing on SEC EDGAR